ResMed sells MatrixCare to Frazier Healthcare for $490M cash; sharpens focus on sleep health

RESMED INC

All-cash deal valued at $490M, subject to closing adjustments; expected to close in Q1 FY2027.
MatrixCare had ~$220M revenue and ~$55M non-GAAP operating profit in FY2026.
Net proceeds to be used for share repurchases (ASR) and general corporate purposes.
Noctrix acquisition expected to add ~$30M revenue but reduce non-GAAP diluted EPS by ~$0.20 in FY2027.
ResMed reiterates FY2026 non-GAAP margin, SG&A, R&D, and tax rate outlook; full FY2027 guidance on Aug 6 call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.